Two Sigma Investments
ADCT icon

Two Sigma Investments’s ADC Therapeutics ADCT Stock Holding History

Two Sigma Investments’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.51M Buy
668,022
+548,561
+459% +$2.16M ﹤0.01% 2592
2025
Q4 		$422K Buy
119,461
+74,003
+163% +$300K ﹤0.01% 3403
2025
Q3 		$182K Buy
+45,458
New +$143K ﹤0.01% 3391
2025
Q2 		– Sell
-44,686
Closed -$63K – 3156
2025
Q1 		$63K Sell
44,686
-138,545
-76% -$235K ﹤0.01% 3020
2024
Q4 		$365K Sell
183,231
-62,022
-25% -$162K ﹤0.01% 2670
2024
Q3 		$773K Sell
245,253
-83,511
-25% -$263K ﹤0.01% 2261
2024
Q2 		$1.04M Buy
328,764
+273,851
+499% +$1.09M ﹤0.01% 1961
2024
Q1 		$247K Buy
+54,913
New +$203K ﹤0.01% 2636
2023
Q2 		– Sell
-223,827
Closed -$436K – 2975
2023
Q1 		$436K Buy
223,827
+168,931
+308% +$623K ﹤0.01% 2265
2022
Q4 		$211K Buy
+54,896
New +$220K ﹤0.01% 2372
2021
Q1 		– Sell
-21,997
Closed -$704K – 3754
2020
Q4 		$704K Buy
+21,997
New +$721K ﹤0.01% 2253

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments's ADCT Position: Q1 2026 in Review

Two Sigma Investments increased its ADC Therapeutics (ADCT) stake by 459% in Q1 2026, buying an estimated $2.16M and bringing the position to 668,022 shares worth $2.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2592.

Two Sigma Investments first reported a position in ADCT in Q4 2020 and has held it in 11 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Two Sigma Investments held 668,022 shares of ADC Therapeutics worth $2.51M as of Q1 2026.
  • Two Sigma Investments bought 548,561 ADC Therapeutics shares in Q1 2026, an estimated $2.16M.
  • ADC Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2592 holding.
  • Two Sigma Investments first reported a position in ADC Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.